N. Manilo

发表

Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission.

L. Terslev, M. Østergaard, K. Asmussen, 2021, Rheumatology.

University of Southern Denmark Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry Ibfelt, Else

Ada, Colic, J. Sørensen, 2017 .

Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry

A. Loft, M. Østergaard, U. Tarp, 2012, Annals of the rheumatic diseases.

Association between MRI findings and patient‐reported outcomes in patients with rheumatoid arthritis in clinical remission and at relapse

J. Baker, L. Terslev, M. Østergaard, 2020, International journal of rheumatic diseases.

FRI0190 Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry

B. Glintborg, M. Hetland, S. Chrysidis, 2017 .

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

A. Loft, I. Hansen, B. Glintborg, 2017, Annals of the rheumatic diseases.

Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab—a substudy of the optimized treatment algorithm in early RA (OPERA) trial

H. Bliddal, K. Stengaard-Pedersen, H. C. Horn, 2017, Clinical Rheumatology.

Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.

A. Loft, B. Gudbjornsson, B. Glintborg, 2014, Rheumatology.

Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry

A. Loft, J. Sørensen, L. Dreyer, 2017, Clinical epidemiology.

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry

A. Loft, J. K. Pedersen, F. Mehnert, 2022, RMD Open.

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

A. Loft, I. Hansen, F. Mehnert, 2018, Annals of the rheumatic diseases.

Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial

A. Loft, J. K. Pedersen, F. Mehnert, 2021, Annals of the Rheumatic Diseases.

Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors

L. Terslev, M. Ostergaard, K. Asmussen, 2022, RMD Open.

Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors

L. Terslev, M. Østergaard, K. Asmussen, 2018, Rheumatology.

One-Year Clinical Outcomes in 1623 Patients with Inflammatory Arthritis Who Switched from Originator to Biosimilar Etanercept: – an Observational Study from the Danish Danbio Registry

A. Loft, I. Hansen, B. Glintborg, 2017 .

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

A. Loft, I. Hansen, B. Glintborg, 2017, Annals of the rheumatic diseases.